Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
105.76 USD | -3.42% |
|
-0.66% | +25.00% |
Feb. 03 | BofA Adjusts Price Target on Axsome Therapeutics to $143 From $122 | MT |
Feb. 03 | Truist Securities Adjusts Axsome Therapeutics Price Target to $190 From $180, Maintains Buy Rating | MT |
Capitalization | 5.13B 4.96B 4.66B 4.13B 7.34B 449B 8.18B 56.04B 20.82B 184B 19.22B 18.83B 775B | P/E ratio 2024 * |
-19.5x | P/E ratio 2025 * | -49.6x |
---|---|---|---|---|---|
Enterprise value | 5.04B 4.87B 4.58B 4.06B 7.21B 442B 8.04B 55.05B 20.46B 181B 18.88B 18.5B 761B | EV / Sales 2024 * |
13.1x | EV / Sales 2025 * | 7.66x |
Free-Float |
81.71% | Yield 2024 * |
-
| Yield 2025 * | - |
Last Transcript: Axsome Therapeutics, Inc.
1 day | -3.42% | ||
1 week | -0.66% | ||
Current month | -0.66% | ||
1 month | +26.24% | ||
3 months | +16.60% | ||
6 months | +26.13% | ||
Current year | +25.00% |







Director | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | 2012-01-11 | |
Nick Pizzie
DFI | Director of Finance/CFO | 50 | 2018-05-15 |
Mark Jacobson
COO | Chief Operating Officer | 41 | 2014-03-31 |
Manager | Title | Age | Since |
---|---|---|---|
Chairman | 56 | 2012-01-11 | |
Roger Jeffs
BRD | Director/Board Member | 63 | 2014-11-30 |
Mark Coleman
BRD | Director/Board Member | 57 | 2014-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.26% | 0 M€ | 0.00% | - | |
0.14% | 302 M€ | +4.32% | - | |
0.14% | 0 M€ | 0.00% | - |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-3.42% | -0.66% | +12.49% | +246.53% | 5.13B | ||
-1.10% | -3.77% | -11.51% | +5.99% | 81.84B | ||
+6.52% | +16.00% | +40.44% | +52.03% | 56.82B | ||
+1.67% | +0.56% | +111.83% | +112.78% | 37.13B | ||
-0.72% | -1.79% | -41.24% | -36.13% | 20.6B | ||
-0.13% | +5.38% | +410.43% | +867.66% | 14.36B | ||
-1.09% | -0.04% | +29.28% | +1.06% | 14.28B | ||
-0.09% | -0.06% | +85.23% | +149.19% | 13.49B | ||
-0.64% | +0.90% | -28.70% | -28.47% | 12.18B | ||
-0.22% | -0.34% | +10.40% | -43.05% | 11.78B | ||
Average | +0.08% | +1.27% | +61.86% | +132.76% | 26.76B | |
Weighted average by Cap. | +1.05% | +0.71% | +44.68% | +81.41% |
2024 * | 2025 * | |
---|---|---|
Net sales | 386M 373M 351M 311M 552M 33.81B 616M 4.22B 1.57B 13.87B 1.45B 1.42B 58.29B | 637M 616M 579M 514M 912M 55.86B 1.02B 6.97B 2.59B 22.92B 2.39B 2.34B 96.33B |
Net income | -260M -252M -237M -210M -372M -22.81B -415M -2.84B -1.06B -9.36B -975M -955M -39.33B | -112M -109M -102M -90.53M -161M -9.85B -179M -1.23B -456M -4.04B -421M -412M -16.98B |
Net Debt | -89.86M -86.9M -81.71M -72.46M -129M -7.88B -143M -983M -365M -3.23B -337M -330M -13.59B | -247M -239M -225M -200M -354M -21.7B -395M -2.71B -1.01B -8.9B -928M -909M -37.42B |
Date | Price | Change | Volume |
---|---|---|---|
25-02-07 | 105.76 $ | -3.42% | 868,718 |
25-02-06 | 109.50 $ | -3.95% | 717,224 |
25-02-05 | 114.00 $ | +0.96% | 866,571 |
25-02-04 | 112.92 $ | +5.11% | 825,624 |
25-02-03 | 107.43 $ | +0.91% | 966,048 |
Delayed Quote Nasdaq, February 07, 2025 at 04:00 pm EST
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AXSM Stock